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Dengue virus (DEN) is a major public health problem worldwide and causes a spectrum of diseases, for which no antiviral treatments exist.
Peptide-conjugated phosphorodiamidate morpholino oligomers (P-PMOs) complementary to the DEN 5V stem–loop (5VSL) and to the DEN 3V
cyclization sequence (3VCS) inhibit DEN replication, presumably by blocking critical RNA–RNA or RNA–protein interactions involved in viral
translation and/or RNA synthesis. Here, a third P-PMO, complementary to the top of the 3V stem–loop (3VSLT), inhibited DEN replication in BHK
cells. Using a novel DEN2 reporter replicon and a DEN2 reporter mRNA, we determined that the 5VSL P-PMO inhibited viral translation, the 3VCS
P-PMO blocked viral RNA synthesis but not viral translation, and the 3VSLT P-PMO inhibited both viral translation and RNA synthesis. These
results show that the 3VCS and the 3VSL domains regulate DEN translation and RNA synthesis and further demonstrate that P-PMOs are potentially
useful as antiviral agents.
D 2005 Elsevier Inc. All rights reserved.Keywords: Dengue virus; Flavivirus; Translation; RNA synthesis; Antisense; Morpholino oligomerIntroduction
Dengue virus (DEN) causes a spectrum of diseases, from a
self-limited febrile illness (dengue fever) to a potentially fatal
disease (dengue hemorrhagic fever/dengue shock syndrome).
DEN is transmitted to humans primarily by Aedes aegypti and
Ae. albopictus mosquitoes in tropical and sub-tropical regions
of the world, exposing 40% of the world’s population to
potential infection (World Health Organization, 1997). DEN
exists as four serotypes (DEN1–4), of which DEN4 is both the
progenitor and the most distantly related to the other serotypes.
DEN, a positive-strand RNA virus, is a member of the
Flavivirus genus within the Flaviviridae family. Other
flaviviruses include West Nile virus (WNV), yellow fever0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.034
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216 Bethesda, MD 20892, USA.virus (YF), Japanese encephalitis virus (JEV), Murray Valley
encephalitis virus (MVE), and tick-borne encephalitis virus
(TBE) (Westaway et al., 1985), all of which are of major
concern for human health. Flavivirus RNA genomes are
approximately 11 kilobases in length and have a type I 5V cap
structure but are not polyadenylated at the 3V end (Cleaves
and Dubin, 1979; Wengler et al., 1978). Upon entry into a
target cell and release of the viral RNA from the nucleocap-
sid, the genome is translated from a single open reading
frame (ORF), presumably via a cap-dependent scanning
mechanism of translation initiation (Ruiz-Linares et al.,
1989). The viral polypeptide is then co- and post-translation-
ally cleaved into three structural proteins (capsid [C], pre-
membrane [prM], and envelope [E]) and seven non-structural
(NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and
NS5) (Hahn et al., 1988). Non-structural proteins replicate the
viral RNA via a full-length negative-sense RNA intermediate
(Chu and Westaway, 1985; Cleaves et al., 1981; Khromykh et
al., 2000). The flaviviral 5V- and 3V-untranslated regions
(UTRs) contain several conserved sequences and secondary6) 439 – 452
www.e
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translation and RNA synthesis (Markoff, 2003).
In the coding region of C is a conserved sequence of
8 nucleotides (nt) that is complementary to a sequence in theFig. 1. Schematic diagram of the structure of the P-PMO and the targeted locations
PMO. Arg-rich peptide (R9F2C) is conjugated to the 5V end of the P-PMO structur
target sequences in the DEN2 5VUTR. Indicated by lines are target sequences for the D
the DEN2 5VUTR was determined using the mfold web server (Zuker, 2003). (C)
adjacent to the 3VUTR sequence are target sequences for the DEN 3VPKIIA, 3VPK
interactions involved in forming the PKIIA and PKIIB pseudoknot secondary struc
downstream. The secondary structures of the DEN2 3VUTR are based on computer
1991; Olsthoorn and Bol, 2001; Proutski et al., 1999; Shi et al., 1996) and chemic3VUTR. These are referred to respectively as the 5V cyclization
sequence (5VCS) and the 3V cyclization sequence (3VCS)
because they are thought to base pair and assist in the
circularization of the viral RNA (Hahn et al., 1987). Recently,in the DEN 5V- and 3V-UTRs. (A) Schematic diagram of the structure of the P-
e. Panel B represents nucleotide bases A, G, C, or T. (B) Locations of P-PMO
EN 5VSL P-PMO and the 5VAUG P-PMO. The predicted secondary structure of
Locations of P-PMO target sequences in the DEN 3VUTR. Indicated by lines
IIB, 3VCS2/RCS2, 3VCS, and 3VSLT P-PMOs. The shaded regions indicate the
tures; the shaded loop sequence is predicted to interact with the shaded region
predicted secondary structures (Hahn et al., 1987; Mohan and Padmanabhan,
al probing of the terminal 100 nt (Shi et al., 1996).
Table 1
Sequence of P-PMOs used in this study
P-PMO namea Nucleotide sequence
DScr (negative control) 5V-AGT CTC GAC TTG CTA CCT CA-3V
5VSL 5V-GTC CAC GTA GAC TAA CAA CT-3V
5VAUG 5V-GGT TAT TCA TCA GAG ATC TG-3V
3VPKIIA 5V-TAC GCC ATG CGT ACA GCT TC-3V
3VPKIIB 5V-TTC CAG CGA GAC TAC AGC TTC-3V
3VCS2/RCS2 5V-GGT CTC CTC TAA CCT CTA GTC-3V
3VCS 5V-CCC AGC GTC AAT ATG CTG-3V
3VSLT 5V-CCA TTT TCT GGC GTT CTG TG-3V
a All P-PMOs used in this study are conjugated to R9F2 peptide.
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3V-UTRs, named the 5V and 3V upstream AUG regions (UARs),
were shown to be necessary for the circularization of the
genome and for viral replication (Alvarez et al., 2005). The
interaction of the 5V- and 3V-CS is critical for flavivirus RNA
synthesis (You and Padmanabhan, 1999; Khromykh et al.,
2001). The 3VCS is part of a sequence element (CS1) of 23
nucleotides in the 3VUTR that is conserved across all DEN
serotypes (Hahn et al., 1987). In the flavivirus 3VUTR, there is
a second conserved sequence (CS2) that may be repeated
(RCS2) (Hahn et al., 1987). The CS2 and RCS2 of WNV have
been shown to play a role in the regulation of viral RNA
synthesis (Lo et al., 2003). Some flaviviruses, namely JEV,
WNV, and MVE, contain a third conserved sequence (CS3),
which is repeated (RCS3) (Hahn et al., 1987).
The flavivirus 3VUTR also contains several conserved
secondary structures, including pseudoknots (PKIIA and
PKIIB) located upstream of the 3VCS (Olsthoorn and Bol,
2001) and a terminal stem–loop (3VSL) domain immediately
downstream of the 3VCS (Brinton et al., 1986; Hahn et al., 1987;
Mohan and Padmanabhan, 1991). The DEN2 3VSL domain is
critical for viral RNA synthesis (You and Padmanabhan, 1999;
Zeng et al., 1998) and enhances translation (Holden and Harris,
2004). In addition, the 3VSL contains a pentanucleotide loop (5V-
CACAG-3V), which is highly conserved among the flaviviruses
(Wengler and Castle, 1986) and appears to regulate RNA
synthesis (Elghonemy et al., 2005; Khromykh et al., 2003;
Tilgner et al., 2005). Besides the DEN2 3VSL, other sequences
within the DEN2 3VUTR modulate viral translation and
infectivity (Edgil et al., 2003), implicating the DEN 3VUTR in
regulating viral translation in addition to RNA synthesis.
Recently, antisense peptide-conjugated phosphorodiamidate
morpholino oligomers (P-PMOs) were utilized to inhibit DEN
and WNV replication, presumably by sterically interfering with
critical RNA–RNA or RNA–protein interactions involved in
either viral translation or RNA synthesis (Deas et al., 2005;
Kinney et al., 2005). PMOs are DNA-like oligomers, usually
containing 18–25 bases, with six-member morpholine rings
and phosphorodiamidate intersubunit linkages (Fig. 1A). They
contain the same purine and pyrimidine bases as DNA for
Watson-Crick base pairing with complementary target se-
quence. The water-soluble structure allows the PMO to base
pair with RNA in a stable and sequence-specific manner
without inducing RNase H degradation. An arginine-rich
peptide conjugated to the 5V end of the P-PMOs allows for
efficient uptake in cell culture (Moulton et al., 2004). A P-
PMO complementary to the first 20 bases of the WNV RNA
genome, named ‘‘5VEND’’, interfered with viral replication
likely via inhibition of the translation process, and a P-PMO
complementary to the WNV 3V cyclization region, named
‘‘3VCSI’’, presumably acted by interfering with RNA synthesis
(Deas et al., 2005). However, the mechanisms by which the
analogous DEN-targeted P-PMOs, named ‘‘5VSL’’ and ‘‘3VCS’’,
inhibit DEN replication have not been determined (Kinney et
al., 2005).
In this study, the DEN 5VSL and 3VCS P-PMOs were
compared to a set of newly designed P-PMOs that werecomplementary to conserved domains in the DEN 3VUTR to
evaluate their relative effectiveness in inhibiting DEN
replication. The mechanism by which the DEN-specific P-
PMOs inhibited viral replication was explored using a DEN2
reporter mRNA and a newly constructed DEN2 reporter
replicon. A novel P-PMO, complementary to the top of the
DEN 3VSL, decreased viral replication apparently by inhibit-
ing both viral translation and RNA synthesis. The DEN 5VSL
P-PMO interfered only with viral translation, similar to the
WNV 5VSL P-PMO (Deas et al., 2005). The DEN 3VCS P-
PMO reduced viral RNA synthesis and did not inhibit viral
translation, as did the WNV 3VCSI P-PMO (Deas et al.,
2005). These DEN-specific P-PMOs are not only useful for
dissecting critical domains involved in DEN translation and
RNA synthesis but are also potentially useful as therapeutics
for human infections.
Results
Design of P-PMOs complementary to conserved domains of
the DEN2 3VUTR
In this study, P-PMOs were designed to be complementary
to several conserved domains within the DEN2 3VUTR for the
purpose of providing insight into how these domains regulate
DEN replication. Two P-PMOs, ‘‘3VPKIIA’’ and ‘‘3VPKIIB’’,
were designed to potentially disrupt the RNA–RNA interac-
tion of the two DEN2 pseudoknot structures (Fig. 1C; Table 1),
which appear to play a role in regulating translation of DEN2
reporter mRNA (Holden and Harris, unpublished data).
Another P-PMO, ‘‘3VCS2/RCS2’’, was designed to base pair
with either CS2 or RCS2 as the sequence of the P-PMO is
complementary to both sequence elements. The DEN P-PMO,
‘‘3VSLT’’, was designed to target the top of the 3VSL, including
the highly conserved pentanucleotide loop (Wengler and
Castle, 1986).
Two P-PMOs were used as positive controls in these
studies, as they were recently shown to decrease DEN
replication (Kinney et al., 2005). These two P-PMOs,
‘‘5VSL’’ and ‘‘3VCS’’, are complementary to the first 20
nucleotides (nt) of the 5VUTR and to the 3VCS region,
respectively. The first 69 nt of the flavivirus 5VUTR forms a
stable conserved stem–loop structure (Brinton and Dispoto,
1988) that is necessary for viral replication (Cahour et al.,
Fig. 2. Effects of P-PMOs on productive infection of BHK cells with DEN2 strain 16681. BHK cells were treated with 5 AM P-PMO and infected with DEN2
strain 16681 at an MOI of 3. At 24 hpi, supernatants were harvested, and DEN titers were determined by viral plaque assay. Error bars indicate the standard error
of the mean (SEM) of at least three independent experiments. DEN P-PMOs that significantly decreased viral titers compared to the DScr P-PMO ( P < 0.05) are
indicated by **.
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were included as negative controls. The ‘‘DScr’’ P-PMO
consisted of randomly generated sequence of 50% G/C
content and lacks any significant complementarity to DEN
sequence. This P-PMO acts as a control for non-specific
cellular and viral effects of the P-PMO oligomer chemistry.
The other negative control, the ‘‘5VAUG’’ P-PMO, is
complementary to the region surrounding the start codon at
the 5V end of the RNA genome and was previously shown to
have minimal effect on DEN replication in Vero cells
(Kinney et al., 2005).
The DEN 3VSLT P-PMO inhibits DEN2 viral replication in
BHK cells
This panel of P-PMOs consists of the 5VSL, 5VAUG, 3VPKIIA,
3VPKIIB, 3VCS2/RCS2, 3VCS, 3VSLT, and DScr P-PMOs, and
they were tested for their ability to inhibit a single cycle of DEN2
replication in BHK cells. Cells were pre-treated with 5 AM ofFig. 3. Specific dose– response inhibition of DEN2 replication by the DEN 3VSL
incubated with different concentrations (1–25 AM) of the DEN 3VSLT P-PMO and
and compared to the absence of P-PMO (set at 100%). Error bars indicate the SE
viability was observed between the 3VSLT P-PMO and the DScr P-PMO at all conc
viability when present at 25 AM. (B) Inhibition of DEN2 replication in a dose-depe
3 and treated with either the DEN 3VSLT P-PMO or the DScr P-PMO at concentra
and DEN titers were determined by viral plaque assay. Error bars indicate the SEM
P-PMO that resulted in significantly different titers compared to treatment with thP-PMO for 3 h before infection with DEN2 strain 16681 in the
absence of P-PMO. Pre-treatment of cells with P-PMO was
previously shown to be necessary for maximum antiviral
activity (Kinney et al., 2005). After 2 h of DEN2 adsorption,
virus was removed, and P-PMO-containing medium was added
to the cells. At 24 h post-infection (hpi), supernatant was
removed, and the amount of infectious virus was determined
by viral plaque assay (Fig. 2). As previously demonstrated in
Vero cells (Kinney et al., 2005), both the DEN 5VSL and 3VCS
P-PMOs inhibited DEN2 replication by nearly 1000-fold in
BHK cells (Fig. 2). The 3VSLT P-PMO also inhibited DEN2
replication by nearly 1000-fold. The other P-PMOs (3VPKIIA,
3VPKIIB, 3VCS2/RCS2) and the negative control P-PMOs
(DScr and 5VAUG) lacked significant inhibitory activity against
DEN2 replication in BHK cells (<10-fold). Similar results
were obtained when the supernatant of infected P-PMO-treated
cells was removed at 48 hpi (data not shown). Thus, these
experiments identified a novel P-PMO targeting the top of the
DEN 3VSL that robustly inhibits DEN2 replication.T P-PMO. (A) Cell viability in the presence of P-PMOs. BHK cells were
the DScr P-PMO for 24 h. Cell viability was determined using an MTS assay
M of at least three independent experiments. No significant difference in cell
entrations. Both P-PMOs had a significant ( P < 0.05) negative impact on cell
ndent manner. BHK cells were infected with DEN2 strain 16681 at an MOI of
tions between 0.05 AM and 12.5 AM. At 24 hpi, supernatants were harvested,
of at least three independent experiments. Concentrations of the DEN 3VSLT
e DScr P-PMO ( P < 0.05) are indicated by **.
Fig. 4. Specificity of inhibition of viral infection by the DEN 3VSLT P-PMO.
BHK cells were treated with either the DEN 3VSLT P-PMO or the DScr P-PMO
(2.5 AM) and infected with DEN1 strain 98J (MOI of 0.5), DEN2 strain PL046
(MOI of 3), DEN3 strain H-87 (MOI of 0.5), DEN4 strain 703-4 (MOI of 0.5),
or SIN-GFP (MOI of 3). Lower MOIs were used for DEN1, DEN3, and DEN4
due to the lower titers obtained for these serotypes. At 24 hpi, supernatants
were harvested, and DEN or SIN titers were determined by viral plaque assay.
Error bars indicate the SEM of at least three independent experiments. Viral
titers that were significantly different ( P < 0.05) after treatment with the DEN
3VSLT P-PMO as compared to the DScr P-PMO are indicated by **.
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low concentrations
To determine which concentrations of the DEN 3VSLT P-
PMO are both non-cytotoxic and effective, a range of
concentrations were tested in a cell proliferation assay and
against DEN2 replication. First, cells were treated with a
range of P-PMO concentrations for 24 h before cell
proliferation was tested using an MTS tetrazolium salt assay
that measures NADH and NADPH produced by living cells
(Fig. 3A). Cell proliferation was non-specifically inhibited at
25 AM of the 3VSLT or DScr P-PMO. Ten micromolars or
less of either P-PMO had no effect on cellular growth. Next,
the inhibition of DEN2 replication due to various concentra-
tions of the 3VSLT and DScr P-PMOs was evaluated (Fig.
3B). Cells were treated with either of the two P-PMOs both
before and after DEN2 infection. Virus production was
determined by performing viral plaque assays on the
supernatant at 24 hpi. Significant inhibition of DEN2
replication was detected when the 3VSLT P-PMO concentra-
tions were between 0.5 AM and 5 AM. The DScr P-PMO
generated non-specific inhibition of DEN2 replication at aTable 2
Alignment of DEN1–4 strains used in this study with the complement of the DEN
Straina Accessi
DEN1 98J Unpubl
DEN2 16681 U87411
DEN2 PL046 Unpubl
DEN3 H-87 M93130
DEN4 703–4 AF3101
a DEN strains used in this study.
b S. Shresta, D. Prigozhin, and E. Harris, unpublished data.
c Sequence is an exact complement to the sequence of the DEN 3VSLT P-PMO. Dconcentration of 12.5 AM. The greatest difference between
the effect of the 3VSLT P-PMO and the DScr P-PMO on
DEN2 replication occurred at 2.5 AM. Therefore, between
0.5 AM and 5 AM of the 3VSLT P-PMO was sufficient to
specifically inhibit DEN2 replication without impairing
normal cellular processes.
BHK cells take up P-PMOs and are infected with DEN2
efficiently
To determine the efficiency of P-PMO uptake by BHK
cells at a concentration (2.5 AM) at which the 3VSLT P-PMO
is both non-cytotoxic (Fig. 3A) and effective (Fig. 3B), the
DScr P-PMO was 3V end-labeled with fluorescein and added
to BHK cells before and after DEN2 infection (Supplemen-
tary Figure). The ability of the cells to become productively
infected was also monitored by immunofluorescence with
antibodies against the DEN NS3 protein. At 24 hpi, over 90%
of the cells contained the fluorescein-labeled P-PMO. In
addition, over 90% of the cells were productively infected
with DEN2. Thus, nearly all of the cells both contained the
fluoresceinated P-PMO and were productively infected with
DEN2.
The DEN 3VSLT P-PMO specifically inhibits DEN
types 1, 2, and 3
The ability of the 3VSLT P-PMO to inhibit other DEN
strains and serotypes as well as an alphavirus was evaluated
in BHK cells to further assess the specificity of the 3VSLT P-
PMO. Cells were treated with the 3VSLT or DScr P-PMO and
infected with different DEN serotypes or with Sindbis virus
(SIN), and viral replication was monitored by viral plaque
assay (Fig. 4). The 3VSLT P-PMO inhibited viral replication of
another DEN2 strain (PL046) over 600-fold, similar to the
effect on DEN2 strain 16681. Similarly, it reduced viral
replication of DEN1 strain 98J and DEN3 strain H-87 by
¨80-fold and ¨15-fold, respectively. The sequence of the
DEN 3VSLT P-PMO was perfectly complementary to the
sequence of DEN types 1, 2, and 3 strains used in this study
(Table 2). DEN4 strain 703-4 was not specifically inhibited
by the 3VSLT P-PMO, probably due to five mismatched base
pairs in the target region in this DEN4 strain (Table 2). The
3VSLT P-PMO had no effect on the replication of SIN,
indicating that this P-PMO is specific for DEN and does not3VSLT P-PMO
on # Sequence (5V–3V)
ishedb CAC AGA ACG CCA GAA AAU GGc
– – – – – – – – – – – – – – – – – – – –
ishedb – – – – – – – – – – – – – – – – – – – –
– – – – – – – – – – – – – – – – – – – –
53 – – – – – – G– – – –G C– – G– – C–
ashes indicate same nt as the first sequence reported.
Fig. 5. DEN-specific P-PMOs inhibit viral translation and/or RNA synthesis
BHK cells were infected with DEN2 strain 16681 and treated with the DEN
specific P-PMOs (5VSL, 3VCS, and 3VSLT) or the DScr P-PMO. (A) Effects o
the DEN-specific P-PMOs on viral RNA accumulation. Cells were harvested a
2, 6, 16, and 24 hpi, and total RNA was isolated. DEN RNA strands were
quantified by real-time RT-PCR using NS1-specific primers. Error bars indicate
the SEM of at least three independent experiments. P-PMOs that resulted in
significantly different numbers of DEN RNA molecules at 24 hpi as compared
to the DScr P-PMO ( P < 0.05) are indicated by **. (B) Effects of the DEN
specific P-PMOs on viral protein accumulation. Cells harvested at 24 hpi were
analyzed by Western blot hybridization using anti-NS1 antibodies and were re
probed using anti-actin antibodies. The limit of detection is 25-fold. A
representative Western blot of three separate experiments is shown.
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3VSLT P-PMO inhibited viral replication only if the comple-
mentary sequence with few mismatches (<5) was present in
the viral genome.
DEN-specific P-PMOs inhibit viral translation and/or RNA
synthesis
P-PMOs are hypothesized to inhibit either viral translation
or RNA synthesis by steric interference with critical RNA–
protein or RNA–RNA interactions involved in these processes.
The three DEN-specific P-PMOs (5VSL, 3VCS, and 3VSLT) were
assessed for their effect on viral translation and RNA synthesis.
For positive-strand RNA viruses, these two viral processes are
dependent on each other; without translation of the viral
genome, RNA synthesis cannot occur, and without viral RNA
synthesis, viral translation can only proceed linearly until the
RNA is degraded. To determine whether each DEN-specific P-
PMO inhibited viral replication through one or both of these
processes, viral protein and RNA levels were monitored in
DEN2-infected cells in the presence or absence of the DEN-
specific P-PMOs or the DScr P-PMO.
Viral RNA was quantified by real-time RT-PCR in which a
region of the NS1 gene was amplified from both the positive-
and negative-sense DEN2 RNA strands present at 2, 6, 16, and
24 hpi (Fig. 5A). The DEN-specific P-PMOs and the DScr P-
PMO had no effect on the amount of viral RNA (Fig. 5A) or on
the amount of cellular h-actin mRNA (data not shown) present at
2 hpi as compared to when no P-PMO was present, indicating
that viral entry was not impacted by the P-PMOs. The DScr P-
PMO non-specifically inhibited viral RNA production at 16 hpi
but resulted in only a four-fold reduction in viral RNA levels at
24 hpi. Both the 5VSL P-PMO and the 3VCS P-PMO inhibited
viral replication, resulting in a 20-fold and 60-fold reduction in
viral RNA by 24 hpi, respectively, as compared to the ‘‘no P-
PMO’’ control. The 3VSLT P-PMO was the most effective P-
PMO tested, reducing viral RNA levels over 450-fold compared
to when no P-PMOwas present during infection. No differences
in the amount of cellular SDHA mRNA existed at 24 hpi
between the different conditions (data not shown), suggesting
that the DEN-specific P-PMOs were specifically impacting viral
RNA synthesis. The reduction of viral RNA was similar in
magnitude to the reduction in virus progeny released at 24 hpi
(Figs. 2, 5A; data not shown), indicating that the differences in
viral titers were not due to the P-PMO blocking the release of
viral progeny from infected cells.
To confirm the observed effect on viral RNA synthesis at 24
hpi, viral protein production at 24 hpi was detected by Western
blot analysis using anti-NS1 antibodies when no P-PMO, a
DEN-specific P-PMO, or the DScr P-PMO was present during
a DEN2 infection (Fig. 5B). The DScr P-PMO caused a slight
non-specific reduction in the amount of viral protein at 24 hpi.
The 5VSL, 3VCS, and 3VSLT P-PMOs each inhibited viral
replication such that NS1 was below the limit of detection
(25-fold difference). The differences in the amount of NS1
were also not due to differences in cell number or gel loading
as similar amounts of actin were detected in each lane on thesame blot. Therefore, the DEN-specific P-PMOs most likely
inhibit DEN replication by interfering with viral translation
and/or viral RNA synthesis, and not by affecting virus entry
into the cells or virus maturation and egress.
DEN-specific P-PMOs regulate translation of a DEN2 reporter
mRNA
The data presented thus far indicate that the DEN-specific
P-PMOs may affect viral translation and/or RNA synthesis,
thereby reducing overall viral replication. To test whether the
P-PMOs affect viral translation independently from viral RNA.
-
f
t
-
-
Table 3
Average translation efficiency of the DEN2 reporter mRNA in the presence of
the DEN-specific P-PMOs
Translation
Efficiency (8 h)a
No P-PMO 100
DScr P-PMO 100 T 10
5VSL P-PMO 5 T 1b
3VCS P-PMO 265 T 60
3VSLT P-PMO 47 T 3b
a To calculate translation efficiency, the luciferase activity was normalized to
the amount of relative luciferase units produced in the absence of P-PMO 8 h
after transfection in three independent experiments. SEM is shown.
b Significantly different from the luciferase activity in the presence of the
DScr P-PMO (P < 0.05).
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(‘‘5VDEN-LUC-3VDEN’’; Fig. 6A) (Holden and Harris, 2004)
was used, which consists of the DEN2 5VUTR plus the first 72
nt of the capsid (C) gene and the DEN2 3VUTR flanking the
firefly luciferase reporter gene. The beginning of C was
included because it contains the 5VCS, which is complementary
to the 3VCS present in the DEN 3VUTR. BHK cells were treated
with a DEN-specific P-PMO, no P-PMO, or the DScr P-PMO
both before and after RNA transfection of the DEN2 reporter
mRNA. RNA transfection efficiency and the stability of the
DEN2 reporter mRNA, as measured using a quantitative real-
time RT-PCR assay, were not affected by treatments with the
different P-PMOs (data not shown). Luciferase activity was
monitored for up to 8 h post-transfection (Fig. 6B, Table 3; the
data in Fig. 6B are representative of three independent
experiments whose average values are presented in Table 3).
The DScr P-PMO had a slight enhancing effect on translation
early after RNA transfection; however, by 8 h post-transfec-
tion, this P-PMO had no effect on the translation of the DEN2
reporter mRNA compared to when no P-PMO was present. The
5VSL P-PMO inhibited translation of the DEN2 reporter
mRNA, reducing translation efficiency by 95% at 8 h post-
transfection compared to either the absence of P-PMO or to theFig. 6. Effects of the DEN-specific P-PMOs on translation of the DEN2
reporter mRNA. (A) Schematic diagram of the DEN2 reporter mRNA.
Indicated are the DEN2 5VUTR (black line), first 72 nt of C (gray box) fused
to the firefly luciferase gene (black box), and the DEN2 3VUTR (black line). (B)
DEN-specific P-PMOs affect translation of the DEN2 reporter mRNA. BHK
cells were treated with the DEN-specific P-PMOs (5VSL, 3VCS, and 3VSLT) or
the DScr P-PMO then transfected with the DEN2 reporter mRNA. P-PMOs
were added back after RNA transfection. Luciferase activity was monitored at
2, 4, 6, and 8 h after transfection. Data shown are representative of three
independent experiments. Error bars indicate the standard deviation (SD) of
duplicate samples. The amount of transfected DEN2 reporter mRNA and the
stabilities of the DEN2 reporter mRNAs were not impacted by the presence of
the P-PMOs, as determined by quantitative real-time RT-PCR (data not shown).presence of the DScr P-PMO. The 3VCS P-PMO appeared to
enhance translation of the DEN2 reporter mRNA over 2.5-fold
compared to either the DScr P-PMO or no P-PMO. In contrast,
the 3VSLT P-PMO reduced the translation efficiency of the
DEN2 reporter mRNA by 50% compared to when no P-PMO
or the DScr P-PMO was present. These results suggest that
both the regions targeted by the 5VSL P-PMO and the 3VSLT P-
PMO are required for efficient translation of the DEN2 reporter
mRNA.
Construction and characterization of a novel DEN2 reporter
replicon
To distinguish between effects of DEN-specific P-PMOs on
viral translation and/or RNA synthesis, a DEN2 reporter
replicon ‘‘DEN2rep-FH’’ (Fig. 7A) was constructed. The
DEN2 infectious clone (Kinney et al., 1997) (pD2/IC, gift of
R. Kinney, Center for Disease Control and Prevention, Fort
Collins, CO) was used as the backbone to construct the DEN2
reporter replicon, in which the firefly luciferase gene replaced
most of the structural genes (see Materials and methods). The
DEN2 reporter replicon should translate and replicate in a
manner similar to wild-type DEN RNA. The DEN2 reporter
replicon is not infectious because it lacks the coding sequences
for structural proteins, which are necessary for assembly. The
DEN2 reporter replicon was transcribed in vitro and transfected
into BHK cells. Luciferase activity was monitored for 96 h post-
transfection (Fig. 7B). Luciferase activity peaked within the
first 8 h, and, by 24 h after transfection, luciferase activity was
significantly reduced. Between 48 and 96 h post-transfection,
luciferase activity increased significantly and to a greater extent
than during the first 12 h. Thus, two peaks of luciferase activity
were generated by the DEN2 reporter replicon: an early peak
between 4 and 8 h post-transfection and a later peak between
48 and 96 h post-transfection.
Mycophenolic acid (MPA), a potent inhibitor of DEN RNA
synthesis (Diamond et al., 2002), was added after RNA
transfection of the DEN2 reporter replicon to determine
whether the first or second peak of luciferase activity
corresponds to RNA synthesis of the DEN2 reporter replicon
(Fig. 7B). MPA significantly inhibited only the appearance of
the later peak (48–96 h post-transfection) and not the first peak
Fig. 7. Effects of the DEN-specific P-PMOs on translation and RNA synthesis of the DEN2 reporter replicon. (A) Schematic diagram of the DEN2 reporter replicon.
Indicated are the DEN2 5VUTR (black line), first 72 nt of C (gray box) fused to the firefly luciferase gene (black box), the FMDV 2Apro (dotted box), the last 90 nt of
E (striped box), the entire NS region (white box), and the DEN2 3VUTR (black line). (B) The DEN2 reporter replicon distinguishes between viral translation and
RNA synthesis. Cells were transfected with the DEN2 reporter mRNA then treated with medium or MPA (3 AM). Luciferase activity was monitored at 4, 8, 24, 54,
72, and 96 h after transfection. Data shown are representative of three independent experiments. Error bars indicate the SD of duplicate samples. The amount of
transfected RNA was not impacted by the presence of the P-PMOs, as determined by quantitative real-time RT-PCR (data not shown). (C) DEN-specific P-PMOs
inhibit translation and/or RNA synthesis of the DEN2 reporter replicon. Cells were treated with the DEN-specific P-PMOs (5VSL, 3VCS, and 3VSLT) or the DScr P-
PMO and transfected with the DEN2 reporter replicon. Luciferase activity was monitored at 4, 6, 8, 12, 24, 48, 72, and 96 h after transfection. Data shown are
representative of three independent experiments. Error bars indicate the SD of duplicate samples. The amount of transfected RNAwas not impacted by the presence
of P-PMO, as determined by quantitative real-time RT-PCR (data not shown).
Table 4
Average translation and replication efficiency of the DEN2 reporter replicon in
the presence of the DEN-specific P-PMOs
Translation
efficiency (8 h)a
Replication
efficiency (96 h)a
No P-PMO 100 100b
DScr P-PMO 136 T 23 38 T 5
5VSL P-PMO 5 T 1b 0.006 T 0.001b
3VCS P-PMO 125 T 14 0.003 T 0.001b
3VSLT P-PMO 59 T 9b 0.006 T 0.001b
a To calculate translation efficiency, the luciferase activity was normalized to
the amount of relative luciferase units produced in the absence of P-PMO 8 h
and 96 h after transfection in three independent experiments. Replication
efficiency is dependent on both translation and RNA synthesis efficiency. SEM
is shown.
b Significantly different from luciferase activity in the presence of the DSc
P-PMO (P < 0.05).
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amount of DEN2 reporter replicon RNA present at 24 h post-
transfection, as determined by quantitative real-time RT-PCR
(data not shown). By inhibiting RNA synthesis, MPA also
interfered with the translation of the DEN2 replicon at later
times post-transfection. This indicates that the first peak of
luciferase activity (4–8 h) correlates with translation of the
DEN2 reporter replicon, whereas the later peak of luciferase
activity (48–96 h) is dependent upon RNA synthesis.
DEN-specific P-PMOs inhibit translation and RNA synthesis of
a DEN2 reporter replicon
The DEN2 reporter replicon was then used to distinguish
between the effect of the DEN-specific P-PMOs on viral
translation and RNA synthesis. Cells were treated with the
different P-PMOs before transfection of the DEN2 reporter
replicon and again after RNA transfection (Fig. 7C, Table 4;
the data in Fig. 7C are representative of three independent
experiments whose average values are presented in Table 4).
The different P-PMOs had no effect on RNA transfection
efficiency as determined by real-time RT-PCR (data not
shown). Luciferase activity was monitored for 96 h. The DScr
P-PMO had a slightly positive effect (24% increase) on the
translation of the DEN2 reporter replicon at 8 h and a negative
impact (40% decrease) on the RNA synthesis peak of the
replicon RNA at 96 h, as compared to the ‘‘no P-PMO’’
control. The 5VSL P-PMO, which inhibited translation of theDEN reporter mRNA (Fig. 6B; Table 3), also inhibited
translation of the DEN2 reporter replicon by 95% (Fig. 7C;
Table 4). As a result, the 5VSL P-PMO inhibited the appearance
of the RNA synthesis peak by over 10,000-fold. The 3VCS P-
PMO slightly enhanced translation of the replicon (17%) but
strongly inhibited the appearance of the RNA synthesis peak of
the DEN2 reporter replicon (10,000-fold), indicating that the
3VCS P-PMO inhibited only viral RNA synthesis. The 3VSLT P-
PMO reduced translation of the DEN2 reporter replicon by
40% and inhibited the second peak of luciferase activity that is
primarily dependent on RNA synthesis by over 10,000-fold.r
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reporter replicon to as great a degree as the 5VSL P-PMO (2-
fold vs. 20-fold); however, the 3VSLT P-PMO reduced the
ability of the DEN2 replicon RNA to synthesize more replicon
RNA as effectively as the 5VSL P-PMO did. The significant
reduction in the replication of the DEN2 reporter replicon by
3VSLT P-PMO indicates that it directly inhibits RNA synthesis
in addition to its effects on translation.
Discussion
Antisense molecules that disrupt RNA–RNA or RNA–
protein interactions that are critical for viral replication are
potentially useful both as therapeutic treatments and as tools to
explore cis-acting elements involved in viral translation and/or
RNA synthesis. In this study, an antisense P-PMO comple-
mentary to the top of the terminal, conserved DEN2 3VSL,
which includes a highly conserved flavivirus pentanucleotide
loop, inhibited viral replication in BHK cells. At a low
concentration, the DEN 3VSLT P-PMO was efficiently taken
up by cells and proved to be non-cytotoxic and effective. The
DEN 3VSLT P-PMO reduced viral replication of DEN types 1,
2, and 3, but not DEN4, likely due to mismatched base pairs
between the P-PMO and target sequence. It appears that the
DEN 3VSLT P-PMO inhibited DEN replication by interfering
with both viral translation and RNA synthesis.
Several other P-PMOs were designed to bind to conserved
domains in the DEN2 3VUTR. Two pseudoknot (PK)
structures, PKIIA and PKIIB, were targeted because they
may be involved in regulating viral translation (K.L. Holden
and E. Harris, unpublished data). PKIIA and PKIIB contain
loops that presumably bind to upstream sequences, forming
pseudoknot structures (Olsthoorn and Bol, 2001). The DEN
PKIIB and PKIIA also contain nearly identical conserved
sequences of 23 nt, called CS2 and RCS2, respectively, which
play a role in regulating RNA synthesis (Lo et al., 2003). P-
PMOs targeting either the loops or the CS2/RCS2 sequences
of both PKs were not effective in reducing viral titers as
compared to the negative control DScr P-PMO. The inability
of these P-PMOs to block viral replication may be due to (1)
inefficient binding to the target sequence, (2) compensation of
the disrupted element by a redundant structure, or (3) lack of a
regulatory role in DEN2 replication by the PK domains in
vitro. To differentiate among these hypotheses, these P-PMOs
could be redesigned, tested in combination, and/or evaluated
in a small animal model.
The effect of both the 5VSL- and the 3VCS-targeted P-PMOs
on DEN and WNV replication was previously reported (Deas et
al., 2005; Kinney et al., 2005). These two P-PMOs were
effective in inhibiting viral replication in monkey (Vero) cells
(Kinney et al., 2005) and in hamster (BHK) cells (Deas et al.,
2005). The 5VSL, 3VCS, and 3VSLT P-PMOs tested in our study
were found to have a negative impact on DEN replication in
BHK cells, complementing the previous studies. The mecha-
nism of inhibition of DEN replication was not previously
investigated for the 5VSL and 3VCS P-PMOs (Kinney et al.,
2005). A 5VSL-targeted P-PMO was found to inhibit WNVtranslation, while the 3VCSI P-PMO inhibited WNV RNA
synthesis without affecting viral translation (Deas et al., 2005),
and our studies of DEN support these WNV findings.
A P-PMO complementary to the top loop of the WNV 3VSL
(‘‘3VLoop’’ P-PMO) was shown previously to moderately
inhibit viral replication by an uncharacterized mechanism
(Deas et al., 2005), whereas the DEN 3VSLT P-PMO inhibited
DEN replication as effectively as the 5VSL or 3VCS P-PMOs in
the present study. We found that the DEN 3VSLT P-PMO
reduced the efficiency of both viral translation and RNA
synthesis. The difference between the results for the WNV
3VLoop P-PMO and for the DEN 3VSLT P-PMO may be due to
slight differences in the target sequence of these P-PMOs or to
differences in how dependent these viruses are on the 3VSL for
viral translation. Deletion of the entire WNV 3VUTR was
reported to have no effect on the translation of a WNV replicon
(Tilgner et al., 2005), and the presence of the WNV 3VSL was
found to have a negative impact on translation of a WNV
reporter mRNA (Li and Brinton, 2001). In contrast, the
deletion of the DEN2 3VSL was shown to decrease translation
efficiency of a DEN2 reporter mRNA (Holden and Harris,
2004), and, in data presented in this study, the DEN 3VSLT P-
PMO inhibited DEN translation of both a DEN2 reporter
mRNA and a DEN2 reporter replicon. In addition, a DEN2
replicon containing mutations in the 3VSLT P-PMO binding
region also demonstrated a significant decrease in translation
efficiency (K. Clyde, K. Holden, and E. Harris, unpublished
data), further implicating the 3VSL region in the regulation of
DEN translation. It is possible that the 3VUTR of these two
flaviviruses control viral translation by somewhat different
mechanisms and/or that the DEN 3VUTR is more critical for
regulation of viral translation than the WNV 3VUTR.
A positive-sense RNA virus genome must negotiate
between being translated by ribosomes starting from the 5V
end and being replicated to generate negative-sense RNA by
the viral replicase initiating at the 3V end. Otherwise, a collision
of translating ribosomes and the viral replicase would result in
premature termination of either or both processes. For example,
poliovirus coordinates viral translation and RNA synthesis by
overlapping regulatory domains within its 5VUTR (Gamarnik
and Andino, 1998). In the case of DEN, the appearance of two
distinct peaks in reporter gene expression for the DEN2
reporter replicon suggests that, up to 8 h post-transfection,
translation occurs, as expected, but at approximately 24 h post-
transfection, translation is suppressed while viral RNA
synthesis is favored. After a sufficient amount of viral RNA
is present, viral protein synthesis resumes. Switching between
the opposing processes of viral translation and RNA synthesis
likely involves the viral UTRs.
It is possible that as a DEN infection progresses within a cell,
the DEN 3VCS and 3VSL, which are in close proximity to each
other in the DEN 3VUTR, may facilitate a switch between viral
translation and RNA synthesis and may be regulated by the
relative amounts of viral proteins and viral negative- and
positive-strand RNAs. Initially, when no viral proteins are
present, the 3VSLmay act to enhance viral translation at initiation
(Holden and Harris, 2004), possibly via an interaction with the
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accumulates to form the viral replicase, the DEN 3VSL may
switch from enhancing viral translation to promoting viral RNA
synthesis via an RNA–RNA or RNA–protein interaction. A
rearrangement of the viral RNA structure at the 3V end may allow
the 3VCS to base pair with the 5VCS to promote viral RNA
synthesis. Concurrently, the 3VUAR, which is located in the
lower stem of the 3VSL, may base pair with the 5VUAR to disrupt
the 3VSL structure (Alvarez et al., 2005). After a sufficient
amount of viral RNA synthesis, the base pairing interactions
between the 5V and 3V ends of the DEN genome may no longer be
favored, and the DEN 3VSL may switch back to promoting viral
translation. Therefore, the DEN 3VCS and 3VSL, possibly in
conjunction with other elements in the DEN 5V- and 3V-UTRs,
may facilitate either DEN translation or RNA synthesis,
depending on RNA–RNA and/or RNA–protein interactions.
An antisense phosphorothioate oligomer that blocks the
translation of CMV immediate early 2 (IE2) mRNA has been
approved by the Federal Drug Administration as an antiviral
therapeutic to treat CMV retinitis (Marwick, 1998), indicat-
ing that antisense molecules are feasible as therapeutics for
viral infections. Antisense molecules of various chemistries
have been demonstrated to inhibit other viral infections (Ma
et al., 2000), including DEN in monkey LLCMK/2 cells
(Raviprakash et al., 1995). In the earlier DEN study, two
phosphorothioate antisense oligos complementary to a
sequence near the 5V start codon and to a sequence near
the top of the 3VSL, but excluding the conserved pentanu-
cleotide loop, moderately inhibited DEN replication (Ravi-
prakash et al., 1995).
Dengue is an important public health problem worldwide.
Because no vaccines or antiviral therapies are currently available
to prevent or cure DEN infections, research that utilizes
antisense or other methodologies to prevent infection or reduce
viremia is necessary. The information acquired from previous
research (Deas et al., 2005; Kinney et al., 2005; Raviprakash et
al., 1995) and this study on antisense molecules may lead to the
development of antiviral compounds that are efficacious,
inexpensive, and well-tolerated to treat DEN infections and
other flavivirus infections.
Materials and methods
Cell lines and viruses
BHK-21 (baby hamster kidney) clone 15 cells were
obtained from B. Childs (Center for Vector-born Diseases,
University of California, Davis, CA). BHK cells were grown at
37 -C and 5% CO2 and were cultured in aMEM supplemented
with 10% fetal bovine serum (FBS) (Omega Scientific,
Tarzana, CA) and 10 mM HEPES. All tissue culture media
and supplements were purchased from Invitrogen (Carlsbad,
CA) except where noted. Cells were passaged every 3–4 days
using HBSS with 3 mM EDTA and 10 mM HEPES to suspend
the monolayer. C6/36 cell line was obtained from ATCC
(Manassas, VA). C6/36 cells were maintained in L15 plus 10%
FBS, 10 mM HEPES, and 100 U/ml penicillin and 100 mg/mlstreptomycin (Pen/Strep) at 28 -C without CO2. DEN was
propagated in C6/36 cells (see below).
DEN1 strain 98J (a 1998 clinical isolate from Guyana),
DEN2 strains 16681 (obtained from Center for Disease Control
and Prevention (CDC), Fort Collins, CO) and PL046 (Taiwa-
nese clinical isolate, gift of Dr. H.Y. Lei, National Cheng Kung
University, Taiwan), DEN3 strain H-87 (CDC), and DEN4
strain 703-4 (CDC) were grown in C6/36 cells and titered using
BHK cells as previously described (Diamond et al., 2000).
DEN viral plaques were allowed to develop for 5–6 days prior
to fixation with 10% formaldehyde and staining with 1%
crystal violet in 30% ethanol, after which plaque forming units
(pfu) per milliliter were calculated. A plasmid containing the
Sindbis genome plus green fluorescent protein (GFP) (Frolova
et al., 2002) was provided by Dr. Ilya Frolov (University of
Texas Medical Branch, Galveston, TX). The plasmid was
linearized with XhoI and transcribed in vitro using RiboMAX
Large Scale RNA production System-SP6 (Promega, Madison,
WI) in the presence of m7GpppG cap analog (New England
BioLabs, Beverly, MA). The SIN-GFP RNA was electropo-
rated into BHK cells, and virus was harvested at 24 h post-
transfection, as previously described (Frolova et al., 2002).
SIN-GFP virus was titered by viral plaque assay as described
above, except that they were fixed 2 days post-infection.
Computer-predicted secondary structures
The secondary structures of the DEN2 strain 16681 5VUTR
and 3VUTR were predicted using the mfold web server at
www.bioinfo.rpi.edu/applications/mfold/old/rna/ under stan-
dard conditions (37 -C) (Zuker, 2003).
P-PMO design and synthesis
An arginine-rich peptide NH2-RRRRRRRRRFFC-NH2
(R9F2C) was covalently conjugated to the 5V end of each P-
PMO (Fig. 1A). The synthesis, conjugation, purification, and
analysis of R9F2C-PMO (abbreviated P-PMO in this report)
compounds were similar to procedures described previously
(Moulton et al., 2004; Summerton and Weller, 1997). Sequences
in the DEN2 positive-strand genomic RNA located in regions
within the DEN2 3VUTR found to be important in the DEN life-
cycle (Elghonemy et al., 2005; Holden and Harris, 2004; Khro-
mykh et al., 2001, 2003; Lo et al., 2003; Tilgner et al., 2005;
You and Padmanabhan, 1999; Zeng et al., 1998; K.L. Holden
and E. Harris, unpublished data) were chosen to design
complementary P-PMO compounds of 18–21 bases in length.
Sequences, name designations, and target locations of the P-
PMOs are described in Table 1 and Figs. 1B and C. The DScr P-
PMO, a randomly generated 20-mer P-PMO with 50% G/C
content, was prepared to control for non-sequence-specific acti-
vity of the R9F2-PMO chemistry. To preclude any unintentional
hybridization events, antisense and negative control P-PMO
sequences were screened using BLAST (http://www.ncbi.nlm.
nih.gov/BLAST/) against all primate mRNA and flaviviral
sequences. Lyophilized P-PMOs were diluted to 2 mM using
filter-sterilized distilled water and were stored at 4 -C.
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BHK cells were seeded in 12-well plates in aMEM with
10% FBS and incubated until the cells were 50–80%
confluent. Cells were washed twice with Virus Production-
Serum Free Media (VP-SFM). Serum-free media is necessary
for efficient uptake of R9F2-PMOs (Neuman et al., 2004). One
milliliter of VP-SFM with the indicated concentration of P-
PMO was added to duplicate wells. Cells were incubated for
2–3 h and washed twice with VP-SFM before viral stocks were
added at the indicated MOI in 200 Al VP-SFM. After 2-
h incubation, cells were washed twice with VP-SFM, and 1 ml
of VP-SFM with the indicated P-PMO was added back to each
well. After a 4-h incubation, FBS was added at a concentration
of 2% (except for the experiments represented in Fig. 2, where
no serum was added back), and, 24 h after viral infection, the
supernatant was removed and stored at 80 -C until viral
plaque assays were performed.
Cell proliferation assay
The linear range of BHK cell proliferation was determined
by plating BHK cells in 100 Al of aMEM supplemented with
10% FBS at a density of 5  103 to 7  105 cells per well in a
96-well plate. Cells were incubated overnight before they were
washed in VP-SFM and returned to the incubator for 1 h.
CellTiter 96 AQueous One Solution Reagent (Promega), which
contains an MTS tetrazolium salt to measure NADPH and
NADH produced from metabolically active cells, was added to
each well as per the manufacturer’s protocol. Cells were
incubated at 37 -C and 5% CO2 for 2 h before the absorbance
was read at 490 nm using an Elx808 Ultra Microplate Reader
(Bio-Tek Instruments, Inc., Winooski, VT) and KCjunior
software (Bio-Tek Instruments, Inc.). To assess the effect of
P-PMOs on cell growth, BHK cells were plated at 4  104 cells
per well in a 96-well plate in 100 Al aMEM with 10% FBS and
were incubated for 4 h. VP-SFM (100 Al) with the indicated
concentration of P-PMO was added to wells in quadruplicate.
Cells were incubated for 24 h, at which point CellTiter 96
AQueous One Solution Reagent (20 Al) was added to each well
and processed as described above. The average background
(medium alone) was subtracted from each well. Cell viability
was calculated by setting the absorbance reading from cells that
were not treated with P-PMO to 100%.
Immunocytochemistry
BHK cells were plated, treated with 3V-end fluorescein
labeled DScr P-PMO, and infected with DEN2 strain 16681 as
described above, except that coverslips were added to each
well before plating the cells. At 24 hpi, cells were washed twice
with PBS and fixed in 4% paraformaldehyde, pH 7.3 for 10
min (min) at room temperature (RT). Cells were washed twice
with PBS before blocking with 5% normal goat serum (NGS)
in HBSS supplemented with 10 mM HEPES and 0.1% saponin
(H/HBSS/S) for 1 h at RT. Cells were incubated with primary
antibody (monoclonal antibody anti-NS3 E1.E6 at a 1:1000dilution) (P.R. Beatty, and E. Harris, unpublished data) in H/
HBSS/S plus 5% NGS overnight at 4 -C followed by three
washes with H/HBSS/S. Cells were incubated with biotinylated
goat anti-mouse antibody (1:300) (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA) in H/HBSS/S for 30 min
followed by three washes with H/HBSS/S and a 30-min
incubation in Vectastain ABC-AP reagent (Vector Laboratories,
Burlingame, CA). Cells were washed as above and incubated
in Vector Red Alkaline Phosphatase substrate (Vector Labora-
tories) until color was visible then counterstained with Hoechst
stain for 10 min at RT. Cells were viewed using a Zeiss
Axiophot epifluorescence microscope with a Photometrics
Quantix cooled digital camera (Tuscon, AZ) and QImaging
Micropublishing was used to capture the image. ATRITC filter
was used for visualizing DEN antigen, an FITC filter for the
fluoresceinated DScr P-PMO, and a UV filter for viewing
cellular nuclei. Photos were merged using Adobe Photoshop
(San Jose, CA).
Quantitative real-time RT-PCR
Cells were harvested at the times indicated using 500 Al of
TRIZOL (Invitrogen) per well. Samples were kept at 80 -C
until RNA was extracted according to the manufacturer’s
protocol. Total RNA was resuspended in 200 Al RNase-free
ddH2O and stored at80 -C.Quantitative real-timeRT-PCRwas
performed using TRIZOL-extracted total RNA samples and
LUX Fluorogenic Primers (Invitrogen). For quantifying the
amount of DEN RNA, a sequence within NS1 was amplified
using a FAM-labeled forward primer (5V-CAC AAA CCATGA
AGA GGG CAT TTG [FAM]G-3V) and an unlabeled reverse
primer (5V-TTT GTT TCC ACA TCA GAT TCT CCA-3V). For
quantifying reporter mRNAs containing LUC, the target
sequence near the 3V end of LUC was amplified as previously
described (Holden and Harris, 2004). As an internal control,
LUX primers specific for mouse succinate dehydrogenase
complex subunit A flavoprotein (SDHA) with a FAM label or
h-actin with a JOE label (Invitrogen) were used. SuperScript
II Platinum One-Step Quantitative RT-PCR System (Invitro-
gen) and an ABI PRISM 7300 (Applied BioSystems, Foster
City, CA) were used according to the manufacturers’
instructions. A standard curve was generated by diluting a
mixture of total BHK mRNA and either pD2/IC RNA (gift of
R. Kinney, CDC) or LUC mRNA that was transcribed in vitro
as described below.
Western blot analysis
Cells were harvested from 12-well plates 24 hpi using
HBSS/E/H, washed twice in PBS, and lysed in 60 Al of freshly
made lysis buffer (150 nm NaCl, 50 mM Tris pH 8.0, 0.01%
SDS, 1% NP40, 1 mM DTT, and aprotinin) chilled on ice for
20 min. Cellular debris was pelleted by centrifugation (this step
had no impact on the amount of NS1 protein present in the cell
lysate [A.-M. Helt and E. Harris, unpublished data]), and the
protein concentration in the supernatant was determined. Thirty
micrograms of total protein were mixed with loading buffer
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Signaling Technology, Beverly, MA) and a Dual Color
Precision Plus Protein Standard (Bio-Rad Laboratories, Her-
cules, CA) before electrophoresis in an SDS-polyacrylamide
gel (10%). Proteins were transferred to a PVDF membrane
(Millipore, Billerica, MA), which was then blocked in PBS
containing 5% nonfat dry milk and 0.1% Tween-20 (PBS-TM)
overnight at 4 -C. Primary antibodies to DEN NS1 (a 1:1
mixture of 8H7.C10 and 2E9.G4) (P.R. Beatty, and E. Harris,
unpublished data) were diluted 1:7 in PBS-TM and incubated
with the blot for 2 h at RT. Both peroxidase-conjugated
AffiniPure rabbit anti-mouse IgG and IgM antibodies
(1:10,000) (Jackson ImmunoResearch Laboratories, Inc.) and
anti-biotin HRP-conjugated secondary antibodies (1:2000)
(Cell Signaling Technology) were used along with the Super-
Signal West Dura Extended Duration substrate (Pierce, Rock-
ford, IL), and image analysis was performed using a
ChemiDOC system (Bio-Rad Laboratories, Hercules, CA).
The blot was subsequently washed and re-probed with an HRP-
conjugated monoclonal anti-actin antibody (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) for 1–2 h followed by the
West Dura substrate. The limit of detection of the anti-NS1
Western blot was determined by analyzing serial dilutions of
16681-infected cell lysates in a single blot.
Replicon cloning
A panel of sub-genomic DEN2 replicons was constructed by
modification of a molecular clone of the DEN2 strain 16681,
using an approach described initially by Varnavski and
Khromykh (1999). Starting material for the work was a
molecular clone in which the full-length genomic RNA of
the 16681 DEN2 strain was positioned under the transcriptional
control of the T7 promoter (pD2/IC-30P; referred to as pD2/IC)
(Kinney et al., 1997), generously provided by R. Kinney
(Center for Disease Control and Prevention, Fort Collins, CO).
The firefly luciferase gene was placed after the first 72 nt of C
followed by the foot and mouth disease virus 2A self-cleaving
protease (FMDV 2Apro), which was included to cleave the
luciferase protein away from the downstream NS proteins
(Ryan and Drew, 1994). FMDV 2Apro was fused to the last 90
nt of the envelope gene (E), which contains the leader sequence
required for proper topology of the remaining viral polyprotein
in the ER during translation (Bray et al., 1989; Falgout et al.,
1989). All of the non-structural genes and the DEN2 3VUTR
were included downstream of E. The antisense hepatitis delta
virus ribozyme (HDVr) sequence was inserted adjacent to the
DEN2 3VUTR to cleave the in-vitro-transcribed RNA, gener-
ating the correct 3V end (Perrotta and Been, 1990).
Two classes of replicons were constructed under the
transcriptional control of either the T7 or CMV promoters.
While the pDENrep-FH vector used in these studies was
designed downstream of the T7 promoter, it shared many
common cloning intermediates with CMV promoter (‘‘DNA-
launched’’) replicons that will be described elsewhere (T.C.
Pierson and E. Harris, unpublished data). First, the entire 5V end
of the pD2/IC molecular clone was replaced with sequenceencoding a sub-genomic DEN2 RNA that lacked the majority
of the structural genes (residues 26–745), positioned down-
stream of the CMV promoter/enhancer. To do this in the
smallest number of steps, overlapping PCR was performed to
fuse a fragment of a DNA-launched sub-genomic WNV
replicon encoding the CMV promoter, FMDV 2Apro, and a
novel MluI site within the DEN ORF (T.C. Pierson, M.
Sanchez, B.A. Puffer, A.A. Ahmed, B. Geiss, L.E. Valentine,
L.A. Altamura, M.S. Diamond, and R.W. Doms, submitted for
publication) followed by insertion into pD2/IC using unique
SacI and MluI sites. Importantly, the SacI and MluI sites
originally present in pD2/IC were destroyed during this step,
allowing the replacement of WNV sequence (the 5VUTR and 20
aa of C) with sequence encoding the DEN2 5VUTR and 24
residues of C using a single PCR fragment and the novel SacI
and MluI sites. The insertion of the HDVr was also introduced
using overlap extension PCR and unique AvrII and ClaI sites
present in the vector backbone. Subsequently, the firefly
luciferase reporter gene was inserted into the unique MluI site
located just downstream of the FMDV 2Apro (creating
pDIIrep-fLuc). Finally, a fragment containing T7-DEN
5VUTR-luciferase was re-introduced into pDIIrep-fLuc using
unique SphI and KphI sites (located in luciferase and the vector
backbone, respectively) to create pDENrep-FH.
In vitro transcription and RNA transfection
pDENrep-FH was linearized with PstI. pGL3-5VDEN-C72-
LUC-3VDEN (Holden and Harris, 2004) was linearized with
XbaI, leaving 4 nt of vector sequence at the 3V end. After
digestion, plasmid DNA was phenol-chloroform-extracted,
precipitated with sodium acetate, and resuspended to approx-
imately 1 Ag/Al. For in vitro transcription, 1 Ag of linearized
DNA template was used to program RiboMax Large Scale
RNA Production System using T7 RNA polymerase (Promega)
and was incubated at 30 -C (replicon) or 37 -C (reporter). Cap
analog m7GpppA (NEB) was included in the reaction to
incorporate a 5V cap structure into the mRNA. Samples were
treated with DNase I (Promega) for 15 min at 37 -C, and
unincorporated nucleotides were removed using NucAway
Spin Columns (Ambion, Austin, TX). The RNAwas quantified
using a spectrophotometer (Ultrospec 1000, Pharmacia Bio-
tech, England) and stored at 80 -C.
For RNA transfection experiments, BHK cells were seeded
(1  105 cells per well) in 12-well plates and incubated
overnight. Cells were washed with VP-SFM before 2.5 AM P-
PMO in 1 ml VP-SFM was added to each well. Cells were
returned to the incubator for 3 h and then washed twice with
VP-SFM. LipofectAMINE2000 (Invitrogen) was mixed with
either 4 Ag of the DEN2 reporter mRNA or 0.5 Ag of DEN2
reporter replicon RNA, and cells were transfected according to
the manufacturer’s instructions. Transfection was stopped by
washing the cells 2 h after addition of the RNA–Lipofect-
AMINE2000 mixture. Mycophenolic acid (3 AM) (Sigma) or
the P-PMOs in VP-SFM were added to each well, and, after
incubation at 37 -C for 4 h, 20 Al of FBS was added to each
well. Cells were harvested at the times indicated in the figure
K.L. Holden et al. / Virology 344 (2006) 439–452 451legends. Duplicate wells were lysed for luminometry using Cell
Culture Lysis Reagent (CCLR) (Promega), and two other wells
were treated with TRIZOL (Invitrogen) to extract total RNA.
All cell lysates and RNA samples were stored at 80 -C until
processed. To perform luciferase assays, 10 Al of lysate was
mixed with 50 Al Luciferase Assay Reagent (Promega). The
samples, diluted 1:10 in CCRL if necessary, were analyzed
using a TD20/20 luminometer (Turner Designs, Sunnyvale,
CA) with a 3-s delay and a 15-s read.
Statistical analysis and mRNA half-life calculations
Standard deviation, standard deviation of the mean, and
Student’s t test were determined using Microsoft Excel for all
experiments, which were repeated at least three times.
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